When combined with proteasome inhibitors, the pharmacodynamics of AcTor shifts towards the development of a mitochondrial catastrophe in AML, which is durable, broad range, agnostic to <i>TP53</i> mutations and to the acquisition of resistance to common clinical anti-AML drugs. This evidence concerns the gene TP53 and acute myeloid leukemia.